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Abstract
Purpose Little is known about the quality of life following pulmonary embolism (PE). The aim of the study was to assess 
the 12-month illness burden in terms of health-related quality of life (HrQoL) and mortality, in relation to diferences in 
patient characteristics.
Methods The PREFER in VTE registry, a prospective, observational study conducted in seven European countries, was 
used. Within 2 weeks following an acute symptomatic PE, patients were recruited and followed up for 12 months. Associa-
tions between patient characteristics and HrQoL (EQ-5D-5L) and mortality were examined using a regression approach.
Results Among 1399 PE patients, the EQ-5D-5L index score at baseline was 0.712 (SD 0.265), which among survivors 
gradually improved to 0.835 (0.212) at 12 months. For those patients with and without active cancer, the average index 
score at baseline was 0.658 (0.275) and 0.717 (0.264), respectively. Age and previous stroke were signiicant factors for 
predicting index scores in those with/without active cancer. Bleeding events but not recurrences had a noticeable impact on 
the HrQoL of patients without active cancer. The 12-month mortality rate post-acute period was 8.1%, ranging from 1.4% 
in Germany, Switzerland, and Austria to 16.8% in Italy. Mortality difered between patients with active cancer and those 
without (42.7% vs. 4.7%).
Conclusion PE is associated with a substantial decrease in HrQoL at baseline which normalizes following treatment. PE is 
associated with a high mortality rate especially in patients with cancer, with signiicant country variation. Bleeding events, 
in particular, impact the burden of PE.
Keywords Venous thromboembolism · Burden of illness · Mortality · Health-related quality of life · Disease registry
Introduction
Pulmonary embolism (PE) is a relatively common emer-
gency [1, 2]. PE may be unprovoked or as a complication of 
underlying diseases such as cancer, medical conditions, and 
surgical procedures. Several empirical estimates of PE inci-
dence rate from European cohort studies have been reported, 
ranging from 0.19 to 0.6 per 1000 population per year [3–8]. 
In contrast, an incidence-based epidemiological model esti-
mated that the PE incidence rate is 0.95 per 1000 population 
per year in the European Union [9].
PE is, together with deep vein thrombosis (DVT), one 
of two clinical presentations of venous thromboembolism 
(VTE) [2]. Long-term morbidity is related to an increased 
risk of developing recurrent VTE, bleeding, and post-VTE 
complications including chronic thromboembolic pulmo-
nary hypertension (CTEPH) syndrome and post-thrombotic 
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syndrome (PTS) [9]. In comparison to DVT which has been 
better studied with respect to health-related quality of life 
(HrQoL), PE has been under investigated [10]. Some studies 
have reported the impaired HrQoL of PE patients compared 
to that of the normal population [10–12]. A recent study 
in Norway showed that patients with a history of PE have 
statistically signiicant lower EQ-5D-3L index score than 
that of the age/gender-matched control group [10]. So far no 
study has reported HrQOL of PE patients using the 5-level 
EQ-5D instrument (EQ-5D-5L) outside of clinical trials.
PE is associated with increased mortality, with the risk 
being highest soon after diagnosis [13]. It is estimated using 
a modiied incidence-based model that 543,454 VTE-related 
deaths occurred in the European Union in 2004 (popula-
tion 454.4 million) [9], whereas a large European regis-
try reported 30-day all-cause PE mortality rate as 5.9% in 
patients that survived to have the diagnosis conirmed.
In addition, PE is associated with additional resource uti-
lization and indirect costs due to days missed from work and 
work loss [14–17]. Thus, as a whole, PE causes a signiicant 
economic burden to society.
This study aimed to contribute to the current knowl-
edge on the HrQoL of patients with PE in Europe using the 
results from the PREFER in VTE registry. At the time of the 
study, a signiicant number of patients without active can-
cer received non-VKA oral anticoagulant (NOAC) therapy 
in place of conventional therapy with vitamin K antagonist 
(VKA). The primary outcome of the study was HrQoL as 
measured by the EQ-5D-5L, and a secondary aim was to 
assess 12-month mortality. Attention was given to difer-
ences per country and diferences between patients with 
and without active cancer. The association between patient 
characteristics, decreased HrQoL, and increased mortality 
was also investigated. A separate publication is available 
dealing with healthcare resource use and productivity loss 
in patients with PE [15].
Methods
Setting and study population
The PREFER in VTE registry was a prospective, obser-
vational, multicenter study with a follow-up of 12 months 
which enrolled 3545 consecutive patients from 311 cent-
ers in seven European countries: Austria, France, Germany, 
Italy, Spain, Switzerland, and the UK between January 2013 
and July 2014. Prior to study commencement, the registry 
protocol was approved by the responsible ethics commit-
tees for the participating countries and the relevant hospital-
based institutional review boards. All patients enrolled in the 
registry irst provided written informed consent. The outline 
has been described elsewhere [18, 19].
Patients were eligible if they were at least 18 years old, 
and had a symptomatic, objectively conirmed irst time or 
recurrent acute VTE (the index event) deined as either distal 
or proximal deep vein thrombosis, pulmonary embolism, or 
both. Patients were recruited within 2 weeks of the occur-
rence of the index event and no exclusion criteria applied. 
Patients were usually recruited post the acute phase of ther-
apy which usually lasts 5–14 days. At baseline, patients were 
assessed face to face to ascertain demography, previous clin-
ical events, risk factors, comorbidities, PE/DVT symptoms, 
and previous VTE treatment. At 1, 3, 6, and 12 months, 
information regarding clinical events (such as VTE events 
[recurrence] or bleeds occurring during follow-up), treat-
ment, resource utilization, health-related quality of life, and 
treatment satisfaction during each follow-up interval was 
collected through telephone calls. The current study con-
cerned PE patients only. PE patients were deined as patients 
that had either a PE with DVT or a PE without DVT. A total 
of 1399 PE patients were recruited in the registry.
Data quality control
The validity of the data was assured by training on data col-
lection ensuring a uniformity and random audits were per-
formed. During these visits, the monitor veriied informed 
consent documentation, source data against medical records, 
and consecutiveness of enrolment. Hospitals and specialized 
outpatient centers were included. As hospital-based investi-
gators do not always follow patients for routine care, patients 
were also asked to participate in follow-ups by phone, safe-
guarding the collection of resource consumption data. Infor-
mation was collected directly from the patients during stand-
ardized phone calls at 1, 3, 6, and 12 months. Data were 
checked electronically for completeness and plausibility at 
the time of entry and additional validation was performed.
Outcomes
Health-related quality of life was assessed by EQ-5D-5L 
[20]. EQ-5D-5L has 5 dimensions: mobility, self-care, 
usual activities, pain/discomfort, and anxiety/depression. 
Within each dimension, one may have no problem, slight 
problems, moderate problems, severe problems, or extreme 
problems (5 levels) [20]. Based on the individual response 
to the descriptive system (5 dimensions and their responses), 
a health state can be deined (e.g., 11111 or 21112). For 
each health state, an index score can be assigned, which 
represents social preference towards each state. The primary 
outcome of interest was EQ-5D-5L scores, including the 
distribution and EQ-5D-5L index score. The secondary out-
comes were 12-month mortality rates. Following enrolment 
in the registry, mortality data were collected at baseline and 
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at each follow-up (1, 3, 6, and 12 months) through a stand-
ardized questionnaire illed out by the investigator.
Health‑related quality of life
EQ-5D-5L scores, both the distribution of responses of each 
dimension and EQ-5D-5L index score, were presented at 
baseline and each follow-up point by country and cancer 
subgroups. The population reference values of EQ-5D-5L 
index scores, based on the UK EQ-5D-5L valuation study 
[21], were used to compare with those of the PE population. 
The extent to which the EQ-5D index score was afected by 
baseline characteristics (age, gender, BMI, previous clinical 
events, clinical factors [excluding provoked], comorbidities 
[excluding cardiovascular disease], and risk factors) plus 
follow-up events (VTE events [recurrence] or bleeds occur-
ring during follow-up) was assessed. The choice was made 
to exclude symptoms at baseline from the analysis, as the 
inclusion of PE symptoms leads to bias in the coeicients of 
the other baseline characteristics, impairing the interpreta-
tion of the impact of these variables on health-related quality 
of life. Moreover, PE symptoms and health-related quality 
of life are highly correlated. Treatment was not included in 
the analyses as this was highly correlated with country, as 
NOACs were not being reimbursed in Italy and Spain at the 
time of the data collection. Tobit regression with repeated 
measures was used to capture the fact that there is an upper 
limit of one and multiple data points from the same patient 
(maximum of 5 data points per patient).
Mortality
12-month mortality rates were assessed by country and dis-
tinguishing between patients with active cancer and with-
out active cancer. Additionally, the observed mortality rates 
were compared with the age- and gender-matched mortality 
rate from the UK general population (year 2013) [22]. The 
association between mortality and baseline characteristics 
(the same as those in the QOL analysis plus PE symptoms 
and EQ-5D-5L index score at baseline) was examined. In 
addition to the evaluation of the total patient population, 
a distinction was made between patients with or without 
active cancer. Lacking exact death dates, logistic regression 
with backward stepwise elimination was used to analyze the 
mortality data instead of Cox-regression. In logistic regres-
sion models, all baseline characteristics were considered and 
selected by backward stepwise elimination. Furthermore, the 
regression was carried out with and without health-related 
quality of life at baseline (the presenting EQ-5D-5L index 
scores) as a predictor because quality of life may afect 
mortality but that also a high probability of mortality may 
afect quality of life. In these analyses including EQ-5D-5L 
index scores, PE symptoms were excluded because of the 
correlation between PE symptoms and baseline EQ-5D-5L 
index score. Analyses of country diferences were addressed 
in an additional analysis.
Analyses and statistics
Descriptive statistics of baseline measurements were pro-
vided, including demographics, clinical factors (previous 
VTE event, PE with DVT and provoked1), previous clini-
cal events (within 3 years prior to enrollment: myocardial 
infarction, coronary heart disease, percutaneous coronary 
intervention, atrial ibrillation, transient ischemic attack, 
stroke, and bleeding event), risk factors (within the past 
3 months or ongoing: active cancer, prolonged immobili-
zation (> 5 days in bed), varicose veins, history of major 
surgery or trauma), comorbidities (hypertension, conges-
tive heart failure, vascular disease, dyslipidemia, diabetes, 
chronic venous insuiciency, renal disease, liver disease, 
chronic respiratory disease, arthritis, bone fracture/soft tis-
sue trauma, lower extremity paralysis, alcohol use, smoking 
history, thrombophilia, and cardiovascular disease), and the 
presence of PE symptoms. Treatment at baseline, i.e., the 
use of heparin, vitamin K antagonists (VKA), or direct oral 
anticoagulants (DOACs), was tabulated. Patients receiving 
ongoing treatment for cancer were labeled as “active can-
cer” patients. Country-speciic diferences were analyzed in 
which Austria, Switzerland, and Germany were combined 
into one pre-speciied region label (DACH). The DACH 
countries that were grouped in a cluster as patient popula-
tion, practice patterns, and healthcare systems were assumed 
to be similar and the numbers of sites for Germany, Austria, 
and Switzerland were, respectively, 74, 5, and 3. Detailed 
clinical variables can be found elsewhere [19].
Missing data and sensitivity analysis
There was missing information (loss to follow-up, death, 
or incomplete data). No imputation was conducted for any 
missing value in the above main analysis. However, the dif-
ference in baseline characteristics between patients who 
completed the follow-ups and those who did not were tested, 
using χ2, rank sum test, or t test when appropriate. Further-
more, a sensitivity analysis, using the multiple imputation 
technique to generate values for missing data, was conducted 
to evaluate the potential impact of missing data. Following 
the technique of chained equations, 20 imputation datasets 
were generated. [23] Baseline characteristics and available 
index scores at diferent time points were used for imputing 
missing data.
1 Provoked PE was deined as having prolonged immobiliza-
tion, > 5 days in bed, or history of major surgery or trauma.
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Results
Patient characteristics
The registry enrolled 1399 PE patients, and baseline char-
acteristics are listed in Table 1. 25.2% of patients were 
from France, followed by Italy 23.7%, Spain 23.4%, DACH 
17.2%, and UK 10.5%. The most common comorbidity was 
hypertension (46.3%). In 8.6% of patients, active cancer 
was diagnosed. The most common reported PE symptoms 
included dyspnea and chest pain, 75.6% and 45.5%, respec-
tively. The majority of patients received heparin at baseline 
(85.4%). VKA was prescribed for 57.4% of patients and 
21.2% used NOACs (mostly used in patients in France and 
DACH, 32.6% and 55.2%, respectively). The detailed base-
line characteristics of the country subgroup can be found 
elsewhere [15].
Patients with active cancer were signiicantly older, and 
had lower BMI and the PE was more often diagnosed with 
a DVT. Patients without active cancer reported dyspnea and 
chest pain more often.
The percentage of active cancer patients difered substan-
tially between countries. In DACH and the UK, less than 
3% of the included patients had active cancer, in France 
7%, and in Italy and Spain more than 12% of the patients 
that were included had active cancer. At baseline, patients 
with active cancer were most often treated with heparin and 
signiicantly less (than patients without active cancer) with 
VKAs or NOACs.
Missing data
It was found that patients who did not complete EQ-5D-5L 
at 12-month follow-up were younger, mostly British, with 
more alcohol/smoking history and active cancer, but less PE 
with DVT, hypertension, dyslipidemia, and chronic venous 
insuiciency. Patients with missing data at other follow-
ups were also younger, British, with more smoking history 
and active cancer, but less dyslipidemia and chronic venous 
insuiciency.
Health‑related quality of life
At baseline, 1324 patients filled in EQ-5D-5L, 897 at 
1 month, 809 at 3 months, 748 at 6 months, and 634 at 
12  months. Figure  1 presents the distribution of each 
dimension of EQ-5D-5L and death for patients without 
active cancer (a) and those with active cancer (b). With 
respect to patients without active cancer, all dimensions 
clearly demonstrated a similar trend with patients reporting 
fewer problems or indicating lower severity of problems 
over time, while the number of deaths increased over time. 
Findings were similar for patients with active cancer, less 
obvious in Fig. 1b due to the high mortality rate. For the 
whole cohort, baseline EQ-5D-5L index score was the low-
est (0.712 [SD 0.265]), and gradually improved to 0.788 
(0.212), 0.805 (0.209), and 0.817 (0.213) at 1-, 3-, and 
6-month follow-up, respectively, and inally reached 0.835 
(0.212) at 12-month follow-up. When death was scored as 
zero, the average index score at each follow-up was 0.712 
(0.265), 0.774 (0.234), 0.768 (0.265), and 0.743 (0.330) 
at 1, 3, 6, and 12 months, respectively. The norm value 
index score for an age/gender-matched general population 
is 0.838.
Figure 2 presents the index scores with/without death 
as zero over time by (a) country and (b) cancer subgroups. 
Over time, France, DACH, and Spain had similar index 
scores, whereas Italy consistently had lower scores (Fig. 2a). 
The diference in index scores between cancer subgroups 
remained stable over time (solid lines in Fig. 2b). However, 
when death was scored as zero, the gap between two groups 
increased substantially as a higher proportion of death 
occurred in the cancer group and subsequently lowered the 
average of index score (dashed lines).
The results from the stepwise regression on EQ-5D-5L 
index scores for patients without active cancer—excluding 
the presence of bleeding events and VTE events—showed 
signiicant negative efects of a number of factors, includ-
ing increasing age, being female, increasing BMI, previous 
stroke, prolonged immobilization, > 5 days in bed, with 
comorbidities of vascular disease, diabetes mellitus, chronic 
respiratory disease, arthritis, and bone fracture/soft tissue 
trauma (Table 2). However, having varicose veins or dys-
lipidemia was associated with a higher index score. When 
including VTE events and bleeding events into the model, 
the results showed that only bleeding and not VTE events 
were found to have a signiicant efect on quality of life. For 
patients with active cancer, only age and previous stroke 
were signiicant predictors, while VTE/bleeding events had 
no impact. Furthermore, no country efects were encoun-
tered after including country-specific variables in both 
groups.
The results of sensitivity analysis, addressing potential 
selection bias, were mostly in line with the main results 
above. As shown in Appendix Fig. 3, after the imputa-
tion, the trend of improvement over time was less obvious 
compared to that in the main analysis (without imputa-
tion, Fig. 2b). The same set of signiicant covariates were 
observed in the Tobit regression using imputed data.
Mortality
In total, 8.1% of patients (102 out of total 1263 patients 
with mortality information) died during the 12-month 
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Table 1  Patients’ characteristics at baseline
DACH Austria, Switzerland, and Germany; VTE venous thromboembolism; DVT deep vein thrombosis; VKA vitamin K antagonists; NOAC non-
VKA oral anticoagulants
*Diference between the groups with/without active cancer reached statically signiicant level p < 0.05
Baseline, % Total N = 1399 Active cancer Baseline, % Total N = 1399 Active cancer
No, N = 1279 Yes, N = 120 No, N = 1279 Yes, N = 120
Age, years, mean (SD) 62.3 (17.1) 61.8 (17.4) 67.2 (11.5)* Comorbidities
Male 53.2 52.4 61.7  Active cancer 8.6 0 100
BMI, mean (SD) 28.16 (6.0) 28.4 (5.9) 25.7 (5.5)*  Hypertension 46.3 46.6 43.3
Highest graduation  Congestive heart 
failure
5.9 5.9 6.7
 Primary school 32.0 31.7 35  Vascular disease 7.1 6.8 10*
 Secondary school 41.8 41.9 40.8  Dyslipidemia 26.4 26.2 28.3
 Above 21.9 22.1 20  Diabetes 11.2 10.8 15
Marital status  Chronic venous insuf-
iciency
14.2 14.5 10.8
 Single 14.2 16.0 9.2  Renal disease 6.4 6.7 4.2
 Married/living as 
married
62.2 61.2 72.5  Liver disease 2.6 2.0 9.2*
 Separated/divorced 5.3 5.7 0.8  Chronic respiratory 
disease
10.7 10.3 15
 Widowed 14.4 14.4 15  Arthritis 6.0 6.3 2.5
 Other 1.2 1.3 0  Bone fracture/soft tis-
sue trauma
10.0 10.3 5.8
Country  Lower extremity 
paralysis
1.1 1.2 0
 France 25.2 25.5 21.7  Thrombophilia 5.1 5.5 0.8*
 DACH 17.2 18.3 5.8  Cardiovascular disease 16.8 16.7 18.3
 Italy 23.7 22.7 35*  Alcohol use 15.6 16.3 7.5*
 Spain 23.4 22.4 34.2*  Smoking history 33.1 32.0 45.8*
 UK 10.5 11.2 3.3 Risk factors (within past 3 month or ongoing)
Previous clinical event (within 3 yr. prior to enroll.)  Prolonged immobiliza-
tion
17.8 17.9 16.7
 Myocardial infarction 3.7 3.8 3.3  >5 day in bed 11.8 11.5 15
 Coronary artery 
disease
3.8 3.8 3.3  Varicose veins 17.5 18.2 10
 Percutaneous coronary 
intervention
2.4 2.4 2.5  Major surg. or trauma 14.0 13.9 15
 Atrial ibrillation 4.7 4.5 7.5 PE symptoms present
 Transient ischemic 
attack
2.65 2.66 2.5  Dyspnea 75.6 76.2 70*
 Stoke 2.7 2.8 1.7  Chest pain 45.5 47.2 28.3*
 Bleeding event 4.2 4.0 6.7  Cough 16.8 16.7 18.3
Clinical factors  Hemoptysis 3.4 3.6 1.7
 Previous VTE event 20.2 20.9 13.3  Syncope 8.2 8.3 6.7
 With concomitant DVT 46.5 45.5 57.5*  Palpitations 7.9 7.7 9.2
 Provoked 27.5 27.3 30  Fever 7.8 7.9 6.7
Baseline treatment  Cyanosis 2.2 2.1 3.3
 Use of heparin 85.4 85.4 84.9  Tachypnea 16.2 16.0 17.5
 Use of VKA 57.4 61.5 13.5*  Tachycardia 16.7 16.4 19.2
 Use of NOACs 21.2 22.7 5.9*  Cardiogenic shock 1.5 1.4 2.5
 Others 7.6 8.0 3.3
 Quality of Life Research
1 3
0
.2
.4
.6
.8
1
0 1 3 6 12
M o b il it y
0
.
2
.
4
.
6
.
8
1
0 1 3 6 12
S e lf - c a re
0
.2
.4
.6
.8
1
0 1 3 6 1 2
U s u a l  a c tiv i t y
0
.2
.4
.6
.8
1
0 1 3 6 12
P a in /D is c o m f or t
0
.
2
.
4
.
6
.
8
1
0 1 3 6 12
A n x ie t y /D e p re s s io n
N o t
S lig h tly
M o d era te ly
S e v er e ly
E x t re m e ly
D e ad
0
.2
.4
.6
.8
1
0 1 3 6 12
M o b il it y
0
.
2
.
4
.
6
.
8
1
0 1 3 6 12
S e lf - c a re
0
.2
.4
.6
.8
1
0 1 3 6 1 2
U s u a l  a c tiv i t y
0
.2
.4
.6
.8
1
0 1 3 6 12
P a in /D is c o m for t
0
.
2
.
4
.
6
.
8
1
0 1 3 6 12
A n x ie t y /D e p re s s io n
N o t
S lig h tly
M o d era te ly
S e v er e ly
E x t re m e ly
D e ad
a
b
Fig. 1  a Distribution of EQ-5D-5L domains and death at baseline and follow-up: patients without active cancer. b. Distribution of EQ-5D-5L 
domains and death at baseline and follow-up: patients with active cancer
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period. Main outcome mortality rate at 12 months difered 
among countries: 5.2% (17/326) in France, 1.4% (3/212) in 
DACH, 16.8% (52/310) in Italy, 9.1% (27/298) in Spain, 
and 2.6% (3/117) in the UK (p value ≤ 0.0001). The mor-
tality rate was signiicantly higher in patients with active 
cancer than in those without active cancer (42.7% vs. 4.7%, 
p value ≤ 0.0001). In comparison, the age- and gender-
adjusted (relecting the total PE study population) mortality 
rate of a UK general population in 2013 is around 2.5%. 
Table 3 presents the cause of death at each follow-up time 
point of total PE patients and by cancer subgroups. Among 
all deaths, only 6.9% were VTE-related—highest in patients 
without active cancer.
Table 4 summarizes the efect of signiicant baseline char-
acteristics on mortality after backward elimination for the 
total patient population, and with a breakdown in patients 
with active cancer and those without, including and exclud-
ing baseline EQ-5D-5L index score as an additional explana-
tory variable. In patients without active cancer, increasing 
age, low BMI, having prolonged immobilization, vascular 
disease, diabetes mellitus, and cardiogenic shock at the time 
of PE diagnosis showed a signiicant association with higher 
all-cause mortality. In active cancer patients, a history of 
smoking and tachycardia were found to be signiicant predic-
tors. When the baseline EQ-5D-5L index score was entered 
into the models, quality of life showed a signiicant asso-
ciation with mortality in both active and non-active cancer 
patients without major changes in the efects of the other 
variables.
After repeating the above regression analyses with the 
addition of “country” as a predictor (UK as the refer-
ence country), France and DACH had significantly lower 
Fig. 2  EQ-5D-5L index score 
at each follow-up, by a. country 
and b. cancer subgroup. a By 
country. Solid line: without 
death as zero; dashed line: 
including death as zero. DACH: 
Austria, Switzerland, and 
Germany. b By active cancer 
subgroup. Solid line: without 
scoring death as zero; dashed 
line: scoring death as zero
Solid line: without death as zero; dashed line: including death as zero. DACH: Austria, Switzerland, and Germany
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Table 2  Analysis of EQ-5D-5L index score, Tobit model with repeated measures results
N number of patients, Obs. number of observations of index scores (per patient could contribute multiple, up to 5, observations), VTE venous thromboembolism
The full list of covariate set includes age, gender, BMI, clinical factors (previous VTE event, PE with DVT), previous clinical events (within 3 years prior to enrollment: myocardial infarction, 
coronary heart disease, percutaneous coronary intervention, atrial ibrillation, transient ischemic attack, stroke, and bleeding event), risk factors (within the past 3 months or ongoing: prolonged 
immobilization (> 5 days in bed), varicose veins, history of major surgery or trauma), comorbidities (hypertension, congestive heart failure, vascular disease, dyslipidemia, diabetes, chronic 
venous insuiciency, renal disease, liver disease, chronic respiratory disease, arthritis, bone fracture/soft tissue trauma, lower extremity paralysis, alcohol use, smoking history, and thrombo-
philia), and VTE/bleeding events during follow-up
Without VTE/bleeding events (n = 1191, Obs = 4024) With VTE/bleeding events
(n = 1191, Obs = 3875)
Coef. Std. Err. p > z [95% Conf. Interval] Coef. Std. Err. p > z [95% Conf. Interval]
Patients without ACTIVE cancer
 Constant 0.974 0.044 < 0.001 0.888 1.060 0.970 0.044 < 0.001 0.884 1.057
 Age − 0.001 0.000 0.006 − 0.002 0.000 − 0.001 0.000 0.011 − 0.002 0.000
 Male 0.105 0.013 < 0.001 0.079 0.131 0.105 0.013 < 0.001 0.079 0.131
 Body mass index − 0.004 0.001 0.001 − 0.006 − 0.002 − 0.004 0.001 0.001 − 0.006 − 0.002
 Previous stroke − 0.115 0.040 0.004 − 0.192 − 0.037 − 0.120 0.040 0.003 − 0.199 − 0.042
 Prolong immobilization − 0.074 0.021 < 0.001 − 0.114 − 0.034 − 0.072 0.021 0.001 − 0.112 − 0.031
 > 5 day in bed − 0.071 0.024 0.003 − 0.118 − 0.023 − 0.068 0.024 0.005 − 0.116 − 0.021
 Varicose veins 0.036 0.017 0.037 0.002 0.070 0.038 0.017 0.03 0.004 0.072
 Vascular disease − 0.092 0.027 0.001 − 0.145 − 0.039 − 0.090 0.027 0.001 − 0.143 − 0.036
 Dyslipidemia 0.040 0.015 0.010 0.010 0.070 0.038 0.015 0.014 0.008 0.068
 Diabetes mellitus − 0.059 0.022 0.007 − 0.101 − 0.016 − 0.055 0.022 0.011 − 0.098 − 0.013
 Chronic respiratory disease − 0.057 0.022 0.009 − 0.100 − 0.015 − 0.059 0.022 0.007 − 0.102 − 0.016
 Arthritis − 0.068 0.026 0.008 − 0.119 − 0.018 − 0.065 0.026 0.013 − 0.116 − 0.014
 Bone fracture/soft tissue trauma − 0.073 0.022 0.001 − 0.116 − 0.030 − 0.074 0.022 0.001 − 0.117 − 0.031
 VTE event during follow-up Not included − 0.061 0.043 0.158 − 0.145 0.024
 Bleeding event during follow-up Not included − 0.050 0.022 0.027 − 0.094 − 0.006
Without VTE/bleeding events (n = 110, Obs = 321) With VTE/bleeding events (n = 110, Obs = 296)
Coef. Std. Err. p > z [95% Conf. Interval] Coef. Std. Err. p > z [95% Conf. Interval]
Patients with ACTIVE cancer
 Constant 1.236 0.161 < 0.001 0.921 1.552 1.237 0.165 0 < 0.001 0.914 1.560
 Age − 0.008 0.002 0.001 − 0.012 − 0.003 − 0.008 0.002 0.001 − 0.013 − 0.003
 Previous stroke − 0.762 0.313 0.015 − 1.376 − 0.148 − 0.758 0.318 0.017 − 1.382 − 0.134
 VTE event during follow-up Not included 0.069 0.182 0.704 − 0.288 0.427
 Bleeding event during follow-up Not included − 0.076 0.091 0.400 − 0.254 0.102
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mortality rates in patients without active cancer (OR 
0.243 and 0.293 for France and DACH, respectively). 
When including quality of life as a predictor, only Italy 
showed a significant association with decreased survival 
compared to the UK (OR 0.3023). By contrast, no country 
effect was found in patients with active cancer.
Discussion
PE patients had worse EQ-5D-5L index scores compared 
to a population norm and the scores gradually improved 
among survivors during the follow-up, with the average 
returning close to the norm. Age and previous stroke were 
independently associated with low index scores in both 
groups with/without active cancer. Furthermore, it was 
found that bleeding, but not recurrences, had an impact on 
HrQoL of patients without active cancer. The study also 
shows that the average mortality rate at 12 months was 
8.1%, varying between countries, and was signiicantly dif-
ferent between patients with active cancer and those with-
out. Signiicant predictors of mortality included increasing 
age, low BMI, prolonged immobilization, vascular disease, 
diabetes mellitus, and presenting with cardiogenic shock 
for patients without active cancer; smoking history and 
tachycardia for patients with active cancer.
Utility
Our inding was aligned with previous studies that reported 
the HrQoL scores of PE patients were lower than those of 
a general population [10, 12, 24]. The reported EQ-5D-3L 
index scores were 0.75 for female and 0.85 for male PE 
patients [10], and 0.68 and 0.82 for VTE patients at base-
line (newly diagnosed) and 3-month follow-up, respec-
tively [25]. However, it should be noted that these scores 
are not directly comparable mainly as our study used EQ-
5D-5L version. The average index score for PE patients at 
baseline was similar to patients who were awaiting renal 
transplantation (0.773) [26]. Although the index scores 
gradually improved among PE survivors during the follow-
up, the average was still lower than the norm (age and 
gender adjusted). Of note, the observed improvement over 
time was driven by the surviving patient population, and 
with the inclusion of patients who died, the average index 
Table 3  Mortality rate by each 
follow-up and cancer subgroup
VTE venous thromboembolism
PE Baseline Month 1 Month 3 Month 6 Month 12
All
 Total 1398 1388 1327 1307 1263
 Death, n(%) 14 (1.00) 34 (2.45) 59 (4.45) 79 (6.04) 102 (8.08)
 Reason for death
  Missing/unknown – 2 (5.9) 2 (3.4) 4 (5.1) 6 (5.9)
  VTE-related death 5 (35.7) 6 (17.6) 7 (11.9) 7 (8.9) 7 (6.9)
  Cardiovascular death 3 (21.4) 5 (14.7) 9 (15.3) 12 (15.2) 18 (17.6)
  Other 6 (42.9) 21 (61.8) 41 (69.5) 56 (70.9) 71 (69.6)
Without active cancer
 Total 1278 1270 1213 1194 1151
 Death, n(%) 11 (0.86) 23 (1.81) 38 (3.13) 45 (3.8) 54 (4.69)
 Reason for death
  Missing/unknown – 1 (4.3) 1 (2.6) 3 (6.7) 2 (3.7)
  VTE-related death 5 (45.5) 6 (26.1) 6 (15.8) 6 (13.3) 6 (11.1)
  Cardiovascular death 2 (18.2) 4 (17.4) 8 (21.1) 11 (24.4) 13 (24.1)
  Other 4 (36.4) 12 (52.2) 23 (60.5) 25 (55.6) 30 (55.6)
With active cancer
 Total 120 118 114 113 112
 Death, n(%) 3 (2.5) 11 (9.32) 21 (18.4) 34 (30.1) 48 (42.9)
 Reason for death
  Missing/unknown – 1 (9.1) 1 (4.8) 1 (2.9) 4 (8.3)
  VTE-related death – – 1 (4.8) 1 (2.9) 1 (2.1)
  Cardiovascular death 1 (33.3) 1 (9.1) 1 (4.8) 1 (2.9) 5 (10.4)
  Other 2 (66.7) 9 (81.8) 18 (85.7) 31 (91.2) 41 (85.4)
 
Q
u
ality o
f Life R
esearch
1
 3
Table 4  Analysis of mortality, logistic regression results adjusted for signiicant baseline variables
The full list of covariate set includes age, gender, BMI, clinical factors (previous VTE event, PE with DVT), previous clinical events (within 3 years prior to enrollment: myocardial infarction, 
coronary heart disease, percutaneous coronary intervention, atrial ibrillation, transient ischemic attack, stroke, and bleeding event), risk factors (within the past 3 months or ongoing: active 
cancer, prolonged immobilization (> 5 days in bed), varicose veins, history of major surgery or trauma), comorbidities (hypertension, congestive heart failure, vascular disease, dyslipidemia, 
diabetes, chronic venous insuiciency, renal disease, liver disease, chronic respiratory disease, arthritis, bone fracture/soft tissue trauma, lower extremity paralysis, alcohol use, smoking history, 
and thrombophilia), the presence of PE symptoms, and EQ-5D-5L index score at baseline
PE pulmonary embolism
a Baseline PE symptoms were not considered in this model (i.e., Dyspnea, Chest pain, Cough, Hemoptysis, Syncope, Palpitations, Fever, Cyanosis, Tachypnea, Tachycardia, Cardiogenic shock, Others.)
Baseline characteristics (n = 1183) Baseline characteristics (excluding PE  Symptomsa) and EQ-5D-5L index score (n = 1198)
Odds ratio Std. err. p value [95% conf. Interval] Odds ratio Std. err. p value [95% conf. Interval]
Total PE cohort
 Constant 0.017 0.018 < 0.001 0.002 0.135 0.201 0.231 0.162 0.021 1.912
 Age 1.046 0.011 < 0.001 1.025 1.068 1.043 0.011 < 0.001 1.022 1.065
 BMI 0.905 0.025 < 0.001 0.857 0.955 0.887 0.026 < 0.001 0.837 0.939
 Active cancer 13.137 3.600 < 0.001 7.678 22.478 12.348 3.495 < 0.001 7.090 21.504
 Prolong immobilization 2.587 0.777 0.002 1.436 4.661
 Vascular disease 2.361 0.789 0.010 1.226 4.545
 Previous AF 2.531 1.007 0.020 1.16 5.52 2.871 1.159 0.009 1.301 6.334
 Smoking history 1.931 0.495 0.010 1.168 3.191 1.967 0.534 0.013 1.155 3.349
 Palpitations 2.276 0.874 0.032 1.072 4.831 Not  includeda
 EQ-5D-5L index score at baseline Not included 0.095 0.040 < 0.001
Baseline characteristics (n = 1071) Baseline characteristics (excluding PE  Symptomsa) and EQ-5D-5L index score (n = 1090)
Odds ratio Std. err. p value [95% conf. Interval] Odds ratio Std. err. p value [95% conf. Interval]
Patients without ACTIVE cancer
 Constant 0.194 0.280 0.257 0.011 3.294 0.502 0.775 0.655 0.024 10.315
 Age 1.058 0.014 < 0.001 1.030 1.086 1.054 0.014 < 0.001 1.027 1.082
 Body mass index 0.796 0.035 < 0.001 0.730 0.869 0.808 0.035 < 0.001 0.742 0.881
 Prolong immobilization 2.570 0.866 0.005 1.328 4.975 2.053 0.737 0.045 1.016 4.148
 Vascular disease 3.580 1.353 0.001 1.707 7.510 2.493 1.014 0.025 1.124 5.531
 Diabetes mellitus 2.575 0.985 0.013 1.217 5.448 2.534 0.996 0.018 1.173 5.474
 Cardiogenic shock 17.573 11.213 < 0.001 5.032 61.373 Not  includeda
 EQ-5D-5L index score at baseline Not included 0.220 0.117 0.004 0.078 0.622
Baseline characteristics (n = 112) Baseline characteristics (excluding PE  Symptomsa) and EQ-5D-5L index score (n = 108)
Odds ratio Std. err. p value [95% conf. Interval] Odds ratio Std. err. p value [95% conf. Interval]
Patients with ACTIVE cancer
 Constant 0.311 0.101 < 0.001 0.164 0.588 3.232 1.934 0.050 1.001 10.440
 Smoking history 2.964 1.246 0.010 1.300 6.758 3.346 1.514 0.008 1.379 8.122
 Tachycardia 6.295 3.633 0.001 2.031 19.510 Not  includeda
 EQ-5D-5L index score at baseline Not included 0.035 0.031 < 0.001 0.006 0.193
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score decreased. Patients who dropped out of the study 
tended to be less healthy and have lower index scores. 
Thus, the trend observed should be interpreted with cau-
tion. As demonstrated in Appendix Fig. 3, after including 
the imputed missing values, the improvement over time 
was minimized.
Among PE patients without active cancer, the efects of 
bleeding were signiicantly associated with a lower quality 
of life as measured by the utility score, but not the efects 
of recurrent VTE. This might be explained by bleeding 
being associated with high morbidity and higher case-
fatality than recurrent VTE [27]. It is possible that there 
was a lack of power to detect changes relating to recurrent 
VTE as around 1% of patients experienced recurrences at 
each follow-up. This association was not observed in the 
patients with active cancer.
We also found that a history of varicose veins and dys-
lipidemia were signiicantly associated with better quality of 
life, which may be due to chance, unobserved interaction, or 
confounding or possibly related to the patients’ interest in 
general health and preventive therapies.
None of the countries were a signiicant predictor of 
HrQoL. However mortality, after correcting for baseline 
characteristics and events, showed signiicant diferences 
between countries. Marvig et al. [25] reported the between-
country diference in HrQoL of VTE patients and suggested 
various factors that might explain the variation, such as dif-
ferent response style, reference levels, external factors, and 
especially cultural diferences. In contrast, across countries 
in our study the diferent case mix might be the main factor 
explaining the data variation, since country data were a non-
signiicant factor predicting the index score after controlling 
for case mix. The lower index score observed in Italy (as 
shown in Fig. 2a) is likely to be explained by the severity of 
cases. More speciically, Italian and Spanish patients were 
recruited from the hospital setting only and had more active 
cancer patients, whereas in France, DACH, and the UK both 
inpatients and outpatients were included. Detailed patient 
characteristics can be found in the accompanying paper [15].
Mortality
The mortality rate at one month was 2.4% and at 12 months 
was 8.1%. This was low compared to the 30-day all-cause 
mortality rate of 5.9% reported in the RIETE registry [14] 
and 5.5% reported in the EMPEROR registry [28]. This 
might be explained by the design of the PREFER registry 
in that patients were recruited in the post-acute treatment 
period, up to two weeks from the occurrence of the index 
event and were to be followed for 12 months. Therefore, 
patients were survivors of the initial period and likely to 
be healthier. In addition, a wide range of 1-year mortality 
rates was observed across countries (from 1.4% in DACH 
to 16.8% in Italy). Several factors might have contributed to 
this variation. Not all countries included the same “mix” of 
patient comorbidities and there was variation in the inpatient 
and outpatient disease management across countries.
The mortality regression results also reflected the 
observed heterogeneity between countries. For instance, 
among patients without active cancer, after controlling for 
case mix (age, gender, BMI, previous clinical events, clini-
cal factors, comorbidities, risk factors and PE symptoms at 
baseline, as well as EQ-5D-5L index score) the survival of 
patients in DACH and France was better than those in the 
UK and Spain, and those in Italy had a worse prognosis. This 
implies that there may still be other factors (residual con-
founding) that contribute to this diference in mortality rates 
in Italy and Spain, which were not included in this analysis. 
Moreover, one might argue that the term ‘country’ efect 
here should be interpreted with caution since PE patients 
recruited in the PREFER study in each country might not 
relect an average PE patient in that country.
This study also showed a signiicantly higher mortality 
rate in patients with active cancer compared with those with-
out. It is generally accepted that 15–20% of all PE patients 
have active cancer at the time of PE diagnosis [29], while 
the proportion of PE patients with active cancer was 8.6% 
in our study. Hence in the PREFER registry in VTE, cancer 
patients were less likely to be included. As such, the current 
mortality estimate can be considered conservative.
It has been reported that the PE associated mortality rate 
has reduced signiicantly over time. In the study by Jiménez 
and his colleagues, based on a large registry, risk-adjusted 
rates of 30-day all-cause mortality decreased from 6.6% dur-
ing 2001–2005 to 4.9% during 2010–2013; rates of 30-day 
PE-related mortality decreased from 3.3 to 1.8% [14]. Their 
study also reported accompanying changes in the length of 
hospital stay (shorter over the years) and changes in the ini-
tial treatment in the same period.
Strengths and limitations
The PREFER in VTE registry provides a rich data source of 
epidemiology, management, and outcomes of VTE based on 
a large registry sample with frequent measurements in a real-
world setting. It collected data from seven European coun-
tries, and provides a very much needed input for overcom-
ing the scarcity of PE evidence originating from the region. 
Furthermore, the design of PREFER—without exclusion 
criteria—allowed all type of PE patients to be recruited, pro-
viding a source of heterogeneous data in a real-world setting. 
The registry was conducted at time when NOAC availability 
varied among countries, ofering a unique opportunity for 
understanding the potential uptake of NOACs.
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Weaknesses include missing data and selection bias 
for healthier patients. Missing data are a common prob-
lem with real-world evidence. There are many possible 
approaches to impute missing values; however, in this 
study the multiple imputation method was employed and 
resulted in a similar inding as that of the main analysis, 
particularly with respect to the factors determining the 
HrQoL. Registries are less selective than clinical trials 
but still select healthier and more compliant patients. Fur-
thermore, the absence of any information on cancer types 
prevents detailed analyses in understanding any possible 
interaction between the type of cancer and PE. That the 
causes of death were not adjudicated by a centralized ad 
hoc committee is also a limitation. A further limitation is 
the multiplicity of the statistical analysis leading to pos-
sible chance indings. Finally, due to the design of the 
registry, the generalizability of country-speciic data might 
be limited.
Conclusion
Reductions in health-related quality of life following 
pulmonary embolism and treatment improved over time 
among survivors. The most concerning complication 
of anticoagulation, bleeding (but not recurrences), had 
an association with worse health-related quality of life. 
This should impact the assessment of risk beneit in the 
era of NOAC therapy, as NOACs result in less bleeding 
compared with VKA. In the post-acute treatment setting, 
mortality rates remained high and were strongly related 
to the presence of active cancer. There also seem to be 
some country diferences in survival following pulmo-
nary embolism. The current study may guide further data 
collection and enhance discussion concerning the man-
agement decisions in order to optimize outcomes for PE 
patients in Europe.
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